Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
204.8 USD | -0.28% | -0.83% | -7.08% |
Apr. 19 | Wolfe Research Adjusts STERIS Price Target to $235 From $245 | MT |
Apr. 11 | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 37.51 and 30.47 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.08% | 20.3B | B- | ||
-3.67% | 186B | C+ | ||
-2.47% | 107B | C | ||
-3.82% | 67.44B | A | ||
+3.19% | 50.03B | B- | ||
+16.06% | 47.81B | B- | ||
+4.79% | 41.03B | B+ | ||
+1.47% | 26.85B | B | ||
+2.30% | 25.82B | A- | ||
-0.76% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- STE Stock
- Ratings STERIS plc